JMJD1C is required for the survival of acute myeloid leukemia by functioning as a coactivator for key transcription factors

Genes and Development

Volumn 29, Issue 20, 2015, Pages 2123-2139

  Chen, Mo ^a   Zhu, Nan ^b,f   Liu, Xiaochuan ^c   Laurent, Benoit ^d,e   Tang, Zhanyun ^a   Eng, Rowena ^b   Shi, Yang ^d,e   Armstrong, Scott A ^b   Roeder, Robert G ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c RUTGERS UNIVERSITY   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f BLOOD RESEARCH INSTITUTE   (United States)

Author keywords

Acute myeloid leukemia; AML1 ETO; HEB; Histone demethylase; LYL1; Transcription regulation

Indexed keywords

HELIX LOOP HELIX PROTEIN; JMJD1C PROTEIN; PROTEIN; TRANSCIPTION FACTOR RUNX1T1; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG; HISTONE DEMETHYLASE; JMJD1C PROTEIN, HUMAN; JMJD1C PROTEIN, MOUSE; N DEMETHYLASE;

ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; TRANSCRIPTION INITIATION; UPREGULATION; ACUTE MYELOID LEUKEMIA; ANIMAL; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION REGULATION; GENETICS; KNOCKOUT MOUSE; METABOLISM; PATHOPHYSIOLOGY; PROTEIN TRANSPORT; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CORE BINDING FACTOR ALPHA 2 SUBUNIT; GENE EXPRESSION REGULATION, LEUKEMIC; JUMONJI DOMAIN-CONTAINING HISTONE DEMETHYLASES; LEUKEMIA, MYELOID, ACUTE; MICE, KNOCKOUT; OXIDOREDUCTASES, N-DEMETHYLATING; PROTEIN TRANSPORT; TRANSCRIPTION FACTORS;

EID: 84944732438     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.267278.115     Document Type: Article

References (70)

1. Ben-Ami O, Friedman D, Leshkowitz D, Goldenberg D, Orlovsky K, Pencovich N, Lotem J, Tanay A, Groner Y. 2013. Addiction of t(8;21) and inv(16) acute myeloid leukemia to native RUNX1. Cell Rep 4: 1131-1143.
2. Bernt KM, Zhu N, Sinha AU, Vempati S, Faber J, Krivtsov AV, Feng Z, Punt N, Daigle A, Bullinger L, et al. 2011. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 20: 66-78.
3. Black JC, Van Rechem C, Whetstine JR. 2012. Histone lysine methylation dynamics: establishment, regulation, and biological impact. Mol Cell 48: 491-507.
4. Brauchle M, Yao Z, Arora R, Thigale S, Clay I, Inverardi B, Fletcher J, Taslimi P, Acker MG, Gerrits B, et al. 2013. Protein complex interactor analysis and differential activity of KDM3 subfamily members towards H3K9 methylation. PLoS One 8: e60549.
5. Cabezas-Wallscheid N, Eichwald V, de Graaf J, Lower M, Lehr HA, Kreft A, Eshkind L, Hildebrandt A, Abassi Y, Heck R, et al. 2013. Instruction of haematopoietic lineage choices, evolution of transcriptional landscapes and cancer stem cell hierarchies derived from an AML1-ETOmouse model. EMBOMol Med 5: 1804-1820.
6. Cerchietti LC, Lopes EC, Yang SN, Hatzi K, Bunting KL, Tsikitas LA, Mallik A, Robles AI, Walling J, Varticovski L, et al. 2009. A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas. Nat Med 15: 1369-1376.
7. Cerchietti LC, Ghetu AF, Zhu X, Da Silva GF, Zhong S, Matthews M, Bunting KL, Polo JM, Fares C, Arrowsmith CH, et al. 2010. A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. Cancer Cell 17: 400-411.
8. Chen X, Skutt-Kakaria K, Davison J, Ou YL, Choi E, Malik P, Loeb K, Wood B, Georges G, Torok-Storb B, et al. 2012. G9a/GLP-dependent histone H3K9me2 patterning during human hematopoietic stem cell lineage commitment. Genes Dev 26: 2499-2511.
9. Daigle SR, Olhava EJ, Therkelsen CA, Majer CR, Sneeringer CJ, Song J, Johnston LD, Scott MP, Smith JJ, Xiao Y, et al. 2011. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 20: 53-65.
10. Dalton WT Jr, Ahearn MJ, McCredie KB, Freireich EJ, Stass SA, Trujillo JM. 1988. HL-60 cell line was derived from a patient with FAB-M2 and not FAB-M3. Blood 71: 242-247.
11. Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, Bantscheff M, Chan WI, Robson SC, Chung CW, Hopf C, Savitski MM, et al. 2011. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478: 529-533.
12. DeKelver RC, Yan M, Ahn EY, Shia WJ, Speck NA, Zhang DE. 2013. Attenuation of AML1-ETO cellular dysregulation correlates with increased leukemogenic potential. Blood 121: 3714-3717.
13. Deshpande AJ, Bradner J, Armstrong SA. 2012. Chromatin modifications as therapeutic targets in MLL-rearranged leukemia. Trends Immunol 33: 563-570.
14. Dignam JD, Lebovitz RM, Roeder RG. 1983. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 11: 1475-1489.
15. El Omari K, Hoosdally SJ, Tuladhar K, Karia D, Hall-Ponsele E, Platonova O, Vyas P, Patient R, Porcher C, Mancini EJ. 2013. Structural basis for LMO2-driven recruitment of the SCL:E47bHLH heterodimer to hematopoietic-specific transcriptional targets. Cell Rep 4: 135-147.
16. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, Morse EM, Keates T, Hickman TT, Felletar I, et al. 2010. Selective inhibition of BET bromodomains. Nature 468: 1067-1073.
17. Gelmetti V, Zhang J, Fanelli M, Minucci S, Pelicci PG, Lazar MA. 1998. Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol 18: 7185-7191.
18. Gorczynski MJ, Grembecka J, Zhou Y, Kong Y, Roudaia L, Douvas MG, Newman M, Bielnicka I, Baber G, Corpora T, et al. 2007. Allosteric inhibition of the protein-protein interaction between the leukemia-associated proteins Runx1 and CBFβ. Chem Biol 14: 1186-1197.
19. Groppe J, Greenwald J, Wiater E, Rodriguez-Leon J, Economides AN, Kwiatkowski W, Affolter M, Vale WW, Izpisua Belmonte JC, Choe S, 2002. Structural basis of BMP signalling inhibition by the cystine knot protein Noggin. Nature 420: 636-642.
20. Heidenreich O, Krauter J, Riehle H, Hadwiger P, John M, Heil G, Vornlocher HP, Nordheim A. 2003. AML1/MTG8 oncogene suppression by small interfering RNAs supports myeloid differentiation of t(8;21)-positive leukemic cells. Blood 101: 3157-3163.
21. Higuchi M, O’Brien D, Kumaravelu P, Lenny N, Yeoh EJ, Downing JR. 2002. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. Cancer Cell 1: 63-74.
22. Kaspers GJ, Zwaan CM. 2007. Pediatric acute myeloid leukemia: towards high-quality cure of all patients. Haematologica 92: 1519-1532.
23. Kim SM, Kim JY, Choe NW, Cho IH, Kim JR, Kim DW, Seol JE, Lee SE, Kook H, Nam KI, et al. 2010. Regulation of mouse steroidogenesis by WHISTLE and JMJD1C through histone methylation balance. Nucleic Acids Res 38: 6389-6403.
24. Kruidenier L, Chung CW, Cheng Z, Liddle J, Che K, Joberty G, Bantscheff M, Bountra C, Bridges A, Diallo H, et al. 2012. A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature 488: 404-408.
25. Laurent B, Ruitu L, Murn J, Hempel K, Ferrao R, Xiang Y, Liu S, Garcia BA, Wu H, Wu F, et al. 2015. A specific LSD1/ KDM1A isoform regulates neuronal differentiation through H3K9 demethylation. Mol Cell 57: 957-970.
26. Lecuyer E, Hoang T. 2004. SCL: from the origin of hematopoiesis to stem cells and leukemia. Exp Hematol 32: 11-24.
27. Lee JW, Choi HS, Gyuris J, Brent R, Moore DD. 1995. Two classes of proteins dependent on either the presence or absence of thyroid hormone for interaction with the thyroid hormone receptor. Mol Endocrinol 9: 243-254.
28. Lee MG, Wynder C, Cooch N, Shiekhattar R. 2005. An essential role for CoREST in nucleosomal histone 3 lysine 4 demethylation. Nature 437: 432-435.
29. Look AT. 1997. Oncogenic transcription factors in the human acute leukemias. Science 278: 1059-1064.
30. Luo X, Liu Y, Kubicek S, Myllyharju J, Tumber A, Ng S, Che KH, Podoll J, Heightman TD, Oppermann U, et al. 2011. A selective inhibitor and probe of the cellular functions of Jumonji C domain-containing histone demethylases. J Am Chem Soc 133: 9451-9456.
31. Lutterbach B, Westendorf JJ, Linggi B, Patten A, Moniwa M, Davie JR, Huynh KD, Bardwell VJ, Lavinsky RM, Rosenfeld MG, et al. 1998. ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors. Mol Cell Biol 18: 7176-7184.
32. Martens JH, Mandoli A, Simmer F, Wierenga BJ, Saeed S, Singh AA, Altucci L, Vellenga E, Stunnenberg HG. 2012. ERG and FLI1 binding sites demarcate targets for aberrant epigenetic regulation by AML1-ETO in acute myeloid leukemia. Blood 120: 4038-4048.
33. Meng YS, Khoury H, Dick JE, Minden MD. 2005. Oncogenic potential of the transcription factor LYL1 in acute myeloblastic leukemia. Leukemia 19: 1941-1947.
34. Meyers S, Downing JR, Hiebert SW. 1993. Identification of AML-1 and the (8;21) translocation protein (AML-1/ETO) as sequence-specific DNA-binding proteins: the runt homology domain is required for DNA binding and protein-protein interactions. Mol Cell Biol 13: 6336-6345.
35. Miyamoto T, Nagafuji K, Harada M, Niho Y. 1997. Significance of quantitative analysis of AML1/ETO transcripts in peripheral blood stem cells from t(8;21) acute myelogenous leukemia. Leuk Lymphoma 25: 69-75.
36. Mulloy JC, Cammenga J, MacKenzie KL, Berguido FJ, Moore MA, Nimer SD. 2002.
37. The AML1-ETO fusion protein promotes the expansion of human hematopoietic stem cells. Blood 99: 15-23.
38. Mulloy JC, Cammenga J, Berguido FJ, Wu K, Zhou P, Comenzo RL, Jhanwar S, Moore MA, Nimer SD. 2003. Maintaining the self-renewal and differentiation potential of human CD34+ hematopoietic cells using a single genetic element. Blood 102: 4369-4376.
39. Murre C. 2005. Helix-loop-helix proteins and lymphocyte development. Nat Immunol 6: 1079-1086.
40. Nimer SD, Moore MA. 2004. Effects of the leukemia-associated AML1-ETO protein on hematopoietic stem and progenitor cells. Oncogene 23: 4249-4254.
41. Ohlsson E, Hasemann MS, Willer A, Lauridsen FK, Rapin N, Jendholm J, Porse BT. 2014. Initiation of MLL-rearranged AML is dependent on C/EBPα. J Exp Med 211: 5-13.
42. Pabst T, Mueller BU, Harakawa N, Schoch C, Haferlach T, Behre G, Hiddemann W, Zhang DE, Tenen DG. 2001. AML1-ETO downregulates the granulocytic differentiation factor C/EBPα in t(8;21) myeloid leukemia. Nat Med 7: 444-451.
43. Park S, Speck NA, Bushweller JH. 2009. The role of CBFβ in AML1-ETO’s activity. Blood 114: 2849-2850.
44. Peterson LF, Zhang DE. 2004. The 8;21 translocation in leukemogenesis. Oncogene 23: 4255-4262.
45. Popovic R, Licht JD. 2012. Emerging epigenetic targets and therapies in cancer medicine. Cancer Discov 2: 405-413.
46. Ptasinska A, Assi SA, Mannari D, James SR, Williamson D, Dunne J, Hoogenkamp M, Wu M, Care M, McNeill H, et al. 2012. Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding. Leukemia 26: 1829-1841.
47. Roeder RG. 2005. Transcriptional regulation and the role of diverse coactivators in animal cells. FEBS Lett 579: 909-915.
48. Saeed S, Logie C, Francoijs KJ, Frige G, Romanenghi M, Nielsen FG, Raats L, Shahhoseini M, Huynen M, Altucci L, et al. 2012. Chromatin accessibility, p300, and histone acetylation define PML-RARα and AML1-ETO binding sites in acute myeloid leukemia. Blood 120: 3058-3068.
49. Schenk T, Chen WC, Gollner S, Howell L, Jin L, Hebestreit K, Klein HU, Popescu AC, Burnett A, Mills K, et al. 2012. Inhibition of the LSD1 (KDM1A) demethylase reactivates the alltrans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat Med 18: 605-611.
50. Schessl C, Rawat VP, Cusan M, Deshpande A, Kohl TM, Rosten PM, Spiekermann K, Humphries RK, Schnittger S, Kern W, et al. 2005. The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice. J Clin Invest 115: 2159-2168.
51. Shia WJ, Okumura AJ, Yan M, Sarkeshik A, Lo MC, Matsuura S, Komeno Y, Zhao X, Nimer SD, Yates JR III, et al. 2012. PRMT1 interacts with AML1-ETO to promote its transcriptional activation and progenitor cell proliferative potential. Blood 119: 4953-4962.
52. Sroczynska P, Cruickshank VA, Bukowski JP, Miyagi S, Bagger FO, Walfridsson J, Schuster MB, Porse B, Helin K. 2014. shRNA screening identifies JMJD1C as being required for leukemia maintenance. Blood 123: 1870-1882.
53. Sun XJ, Wang Z, Wang L, Jiang Y, Kost N, Soong TD, Chen WY, Tang Z, Nakadai T, Elemento O, et al. 2013. A stable transcription factor complex nucleated by oligomeric AML1-ETO controls leukaemogenesis. Nature 500: 93-97.
54. Tripic T, Deng W, Cheng Y, Zhang Y, Vakoc CR, Gregory GD, Hardison RC, Blobel GA. 2009. SCL and associated proteins distinguish active from repressive GATA transcription factor complexes. Blood 113: 2191-2201.
55. Vangala RK, Heiss-Neumann MS, Rangatia JS, Singh SM, Schoch C, Tenen DG, Hiddemann W, Behre G. 2003. The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia. Blood 101: 270-277.
56. Visvader J, Begley CG, Adams JM. 1991. Differential expression of the LYL, SCL and E2A helix-loop-helix genes within the hemopoietic system. Oncogene 6: 187-194.
57. Wadman IA, Osada H, Grutz GG, Agulnick AD, Westphal H, Forster A, Rabbitts TH. 1997.
58. The LIM-only protein Lmo2 is a bridging molecule assembling an erythroid, DNA-binding complex which includes the TAL1, E47, GATA-1 and Ldb1/ NLI proteins. EMBO J 16: 3145-3157.
59. Wang J, Hoshino T, Redner RL, Kajigaya S, Liu JM. 1998. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/ HDAC1 complex. Proc Natl Acad Sci 95: 10860-10865.
60. Wang L, Gural A, Sun XJ, Zhao X, Perna F, Huang G, Hatlen MA, Vu L, Liu F, Xu H, et al. 2011a. The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation. Science 333: 765-769.
61. Wang YY, Zhao LJ, Wu CF, Liu P, Shi L, Liang Y, Xiong SM, Mi JQ, Chen Z, Ren R, et al. 2011b. C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice. Proc Natl Acad Sci 108: 2450-2455.
62. Watanabe S, Watanabe K, Akimov V, Bartkova J, Blagoev B, Lukas J, Bartek J. 2013. JMJD1C demethylates MDC1 to regulate the RNF8 and BRCA1-mediated chromatin response to DNA breaks. Nat Struct Mol Biol 20: 1425-1433.
63. Wilson NK, Foster SD, Wang X, Knezevic K, Schutte J, Kaimakis P, Chilarska PM, Kinston S, Ouwehand WH, Dzierzak E, et al. 2010. Combinatorial transcriptional control in blood stem/ progenitor cells: genome-wide analysis of ten major transcriptional regulators. Cell Stem Cell 7: 532-544.
64. Wolf SS, Patchev VK, Obendorf M. 2007. A novel variant of the putative demethylase gene, s-JMJD1C, is a coactivator of the AR. Arch Biochem Biophys 460: 56-66.
65. Yamane K, Toumazou C, Tsukada Y, Erdjument-Bromage H, Tempst P, Wong J, Zhang Y. 2006. JHDM2A, a JmjC-containing H3K9 demethylase, facilitates transcription activation by androgen receptor. Cell 125: 483-495.
66. Yan M, Burel SA, Peterson LF, Kanbe E, Iwasaki H, Boyapati A, Hines R, Akashi K, Zhang DE. 2004. Deletion of an AML1-ETO C-terminal NcoR/SMRT-interacting region strongly induces leukemia development. Proc Natl Acad Sci 101: 17186-17191.
67. Yan M, Kanbe E, Peterson LF, Boyapati A, Miao Y, Wang Y, Chen IM, Chen Z, Rowley JD, Willman CL, et al. 2006. A previously unidentified alternatively spliced isoform of t (8;21) transcript promotes leukemogenesis. Nat Med 12: 945-949.
68. Zhang J, Kalkum M, Yamamura S, Chait BT, Roeder RG. 2004. E protein silencing by the leukemogenic AML1-ETOfusion protein. Science 305: 1286-1289.
69. Zhou J, Wu J, Li B, Liu D, Yu J, Yan X, Zheng S, Wang J, Zhang L, He F, et al. 2014. PU.1 is essential for MLL leukemia partially via crosstalk with the MEIS/HOX pathway. Leukemia 28: 1436-1448.
70. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, Magoon D, Qi J, Blatt K, Wunderlich M, et al. 2011. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478: 524-528.